STOCK TITAN
  1. Home
  2. News
  3. YMAB

Y-Mabs Therapeutics Inc - YMAB STOCK NEWS

IMPACT
SENTIMENT
YMAB : Nasdaq
Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director
IMPACT
SENTIMENT
YMAB : Nasdaq
Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA
clinical trial
IMPACT
SENTIMENT
YMAB : Nasdaq
Y-mAbs Announces Publication in Cancers
IMPACT
SENTIMENT
YMAB : Nasdaq
Y-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric Oncology
IMPACT
SENTIMENT
YMAB : Nasdaq
Y-mAbs to Participate at Upcoming Investor Conferences in September
conferences
IMPACT
SENTIMENT
YMAB : Nasdaq
Y-mAbs Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
earnings
IMPACT
SENTIMENT
YMAB : Nasdaq
Y-mAbs to Participate at Upcoming Investor Conferences
conferences
IMPACT
SENTIMENT
YMAB : Nasdaq
Y-mAbs to Announce Second Quarter 2023 Financial and Operating Results on August 10, 2023
earnings
IMPACT
SENTIMENT
YMAB : Nasdaq
Y-mAbs Announces Presentation of Naxitamab Data at ASCO
IMPACT
SENTIMENT
YMAB : Nasdaq
Y-mAbs Announces Presentation of GD2-SADA Study at ASCO
Stock YMAB logo
Y-Mabs Therapeutics Inc
Nasdaq:YMAB

YMAB Stock Data

Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link

About YMAB

y-mabs is late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. the company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates - naxitamab and omburtamab - which target tumors that express gd2 and b7-h3, respectively. our mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. with the right partnerships and collaboration, we envision expanding our capabilities to treat adults - changing the course of cancer and its outcome.